A high dose of filgotinib, the JAK1 inhibitor under long-term development by Gilead Sciences Inc. and Galapagos NV, proved effective in a Phase IIb/III study as a treatment for patients with moderately to severely active ulcerative colitis.
Weeks after Mammoth Biosciences announced the company’s CRISPR-based diagnostics test for COVID-19 had a high degree of specificity even for asymptomatic patients, the Bay Area-based firm struck a deal with GlaxoSmithKline to accelerate development of the test in hopes of getting them in consumer hands as soon as possible.
Shares of bluebird bio were down in trading after the U.S. Food and Drug Administration declined to review a Biologics License Application for the experimental CAR-T treatment idecabtagene vicleucel for multiple myeloma co-developed with Bristol Myers Squibb.
Thermo Fisher Scientific Inc. expanded the company’s response to the COVID-19 pandemic by developing a total antibodies test in collaboration with WuXi Diagnostics and Mayo Clinic.
Waltham, Massachusetts-based biotech firm Skyhawk Therapeutics is expanding a strategic collaboration deal with Merck as the two companies are working to develop and commercialize a particular type of therapy built on modulating RNA splicing using Skyhawk’s SkySTAR technology platform.
Cambridge, Massachusetts-based Dyno Therapeutics came out of stealth mode with an official launch of the company’s proprietary CapsidMap platform.
Moderna Inc. and Swiss contract drugmaker Lonza Group AG said on Friday they would accelerate the manufacturing of the U.S. drug developer’s potential coronavirus vaccine.
AstraZeneca and the University of Oxford are partnering on the global development and distribution of Oxford’s COVID-19 vaccine.
Pfizer and Germany-based BioNTech, which are collaborating on a messenger RNA vaccine against SARS-CoV-2, plan to start testing in the United States once the Food and Drug Administration gives clearance.
Numerous major global biopharma companies reported first-quarter 2020 earnings. Typically, the COVID-19 pandemic has affected the companies, although not necessarily in a straightforward way. Many of the companies reported increased sales for the quarter as customers increased stockpiles and inventory in preparation for the pandemic, while other forms of sales and clinical trials were negatively impacted. Here’s a look.